FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089187854> ?p ?o ?g. }

• W3089187854 abstract "Abstract Background For prostate cancer, signaling pathways induced by over-boarding stimulation of G-protein coupled receptors (GPCR) such as the endothelin, α1- and β-adrenergic, muscarinic and angiotensin 1 receptors were accused to support the carcinogenesis. However, excessive receptor stimulation by physiological receptor ligands is minimized by a control system that induces receptor sensitization and down-regulation. This system is missing when so-called “functional autoantibodies” bind to the GPCR (GPCR-AAB). If GPCR-AAB were found in patients with prostate cancer, uncontrolled GPCR stimulation could make these autoantibodies an additional supporter in prostate cancer. Methods Using the bioassay of spontaneously beating cultured rat neonatal cardiomyocytes, GPCR-AAB were identified, quantified and characterized in the serum of 25 patients (aged 56–78 years, median 70 years) with prostate cancer compared to 10 male patients (aged 48–82 years, median 64) with urinary stone disorders (controls). Results Of the cancer patients, 24 (96%) and 17 (68%), respectively, carried autoantibodies directed against the α1-adrenergic receptor (α1-AAB) and endothelin receptor A (ETA-AAB). No patient was negative for both GPCR-AAB. In contrast, ETA-AAB and α1-AAB were absent in all (100%) and 9 (90%) of the 10 control patients, respectively. While α1-AAB targeted a specific epitope of the first extracellular loop of the α1-adrenergic receptor subtype A, an epitope of the second extracellular loop of the ETA receptor was identified as a target of ETA-AAB. As demonstrated in vitro, the functional activity of both autoantibodies found in prostate cancer can be neutralized by the aptamer BC007. Conclusions We hypothesized that α1-AAB and ETA-AAB, which are highly present in prostate cancer patients, could by their functional activity support carcinogenesis by excessive receptor stimulation. The in vitro demonstrated neutralization of α1- and ETA-AAB by the aptamer BC007 could open the door to complement the treatments already available for prostate cancer." @default.
• W3089187854 created "2020-10-01" @default.
• W3089187854 creator A5029951554 @default.
• W3089187854 creator A5031542118 @default.
• W3089187854 creator A5032805530 @default.
• W3089187854 creator A5039014629 @default.
• W3089187854 creator A5055972067 @default.
• W3089187854 creator A5079462263 @default.
• W3089187854 creator A5084769052 @default.
• W3089187854 creator A5088163684 @default.
• W3089187854 date "2020-09-25" @default.
• W3089187854 modified "2023-10-16" @default.
• W3089187854 title "Autoantibodies directed against α1-adrenergic receptor and endothelin receptor A in patients with prostate cancer" @default.
• W3089187854 cites W1522523413 @default.
• W3089187854 cites W1781497087 @default.
• W3089187854 cites W1854984860 @default.
• W3089187854 cites W1978927860 @default.
• W3089187854 cites W1989699585 @default.
• W3089187854 cites W1997132143 @default.
• W3089187854 cites W1999715555 @default.
• W3089187854 cites W2011726833 @default.
• W3089187854 cites W2025925482 @default.
• W3089187854 cites W2043859884 @default.
• W3089187854 cites W2046794040 @default.
• W3089187854 cites W2057824914 @default.
• W3089187854 cites W2071584701 @default.
• W3089187854 cites W2077959784 @default.
• W3089187854 cites W2078617704 @default.
• W3089187854 cites W2079157591 @default.
• W3089187854 cites W2089569798 @default.
• W3089187854 cites W2090406558 @default.
• W3089187854 cites W2092350892 @default.
• W3089187854 cites W2093148351 @default.
• W3089187854 cites W2098393666 @default.
• W3089187854 cites W2104271783 @default.
• W3089187854 cites W2294470418 @default.
• W3089187854 cites W2395913455 @default.
• W3089187854 cites W2402555302 @default.
• W3089187854 cites W2413841675 @default.
• W3089187854 cites W2507350431 @default.
• W3089187854 cites W2550894692 @default.
• W3089187854 cites W2580855485 @default.
• W3089187854 cites W2585599186 @default.
• W3089187854 cites W2588170142 @default.
• W3089187854 cites W2792942476 @default.
• W3089187854 cites W2804306501 @default.
• W3089187854 cites W2900589247 @default.
• W3089187854 cites W2912085287 @default.
• W3089187854 cites W2921084443 @default.
• W3089187854 cites W2943183832 @default.
• W3089187854 cites W2983063065 @default.
• W3089187854 cites W2991205661 @default.
• W3089187854 cites W2791247349 @default.
• W3089187854 doi "https://doi.org/10.1186/s13317-020-00136-y" @default.
• W3089187854 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7519497" @default.
• W3089187854 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32977857" @default.
• W3089187854 hasPublicationYear "2020" @default.
• W3089187854 type Work @default.
• W3089187854 sameAs 3089187854 @default.
• W3089187854 citedByCount "2" @default.
• W3089187854 countsByYear W30891878542021 @default.
• W3089187854 crossrefType "journal-article" @default.
• W3089187854 hasAuthorship W3089187854A5029951554 @default.
• W3089187854 hasAuthorship W3089187854A5031542118 @default.
• W3089187854 hasAuthorship W3089187854A5032805530 @default.
• W3089187854 hasAuthorship W3089187854A5039014629 @default.
• W3089187854 hasAuthorship W3089187854A5055972067 @default.
• W3089187854 hasAuthorship W3089187854A5079462263 @default.
• W3089187854 hasAuthorship W3089187854A5084769052 @default.
• W3089187854 hasAuthorship W3089187854A5088163684 @default.
• W3089187854 hasBestOaLocation W30891878541 @default.
• W3089187854 hasConcept C121608353 @default.
• W3089187854 hasConcept C126322002 @default.
• W3089187854 hasConcept C134018914 @default.
• W3089187854 hasConcept C135285700 @default.
• W3089187854 hasConcept C144980905 @default.
• W3089187854 hasConcept C159654299 @default.
• W3089187854 hasConcept C163764329 @default.
• W3089187854 hasConcept C170493617 @default.
• W3089187854 hasConcept C203014093 @default.
• W3089187854 hasConcept C2780192828 @default.
• W3089187854 hasConcept C502942594 @default.
• W3089187854 hasConcept C71924100 @default.
• W3089187854 hasConcept C86803240 @default.
• W3089187854 hasConceptScore W3089187854C121608353 @default.
• W3089187854 hasConceptScore W3089187854C126322002 @default.
• W3089187854 hasConceptScore W3089187854C134018914 @default.
• W3089187854 hasConceptScore W3089187854C135285700 @default.
• W3089187854 hasConceptScore W3089187854C144980905 @default.
• W3089187854 hasConceptScore W3089187854C159654299 @default.
• W3089187854 hasConceptScore W3089187854C163764329 @default.
• W3089187854 hasConceptScore W3089187854C170493617 @default.
• W3089187854 hasConceptScore W3089187854C203014093 @default.
• W3089187854 hasConceptScore W3089187854C2780192828 @default.
• W3089187854 hasConceptScore W3089187854C502942594 @default.
• W3089187854 hasConceptScore W3089187854C71924100 @default.
• W3089187854 hasConceptScore W3089187854C86803240 @default.
• W3089187854 hasIssue "1" @default.
• W3089187854 hasLocation W30891878541 @default.
• W3089187854 hasLocation W30891878542 @default.

• next